CANCER

Bloodwise 51
Group statement of financial activities for the year ended 31 March 2015
Group statement of financial activities for the year
ended 31 March 2015 (continued)
INCORPORATING THE INCOME AND EXPENDITURE ACCOUNT
Notes
Restricted
Funds
2015 2015 2015 2014
Unrestricted
Funds
Total
Total
£'000 £'000 £'000 £'000
NET INCOMING / (OUTGOING) RESOURCES,
BEING NET EXPENDITURE FOR THE YEAR,
BEFORE TRANSFERS 3 502 (11,475) (10,973) (4,909)
Transfers 14 (502) 502 - -
NET OUTGOING RESOURCES, BEING
NET EXPENDITURE FOR THE YEAR,
BEFORE GAINS - (10,973) (10,973) (4,909)
Realised and unrealised
gains on investments 6
-
- 3,469 3,469 797
NET MOVEMENT IN FUNDS - (7,504) (7,504) (4,112)
Balance brought forward at
1 April 2014 - 11,348 11,348 15,460
Balance carried forward at
31 March 2015 13 - 3,844 3,844 11,348
All amounts relate to the continuing activities of the group.
The group has no recognised gains and losses other than those included in the results above, and therefore
no separate statement of total recognised gains and losses has been presented.
The notes on pages 56 to 65 form part of these financial statements.
Bloodwise trading as Leukaemia & Lymphoma Research Company limited by guarantee 738089
Registered charity 216032 (England & Wales) SC037529 (Scotland)